Table 3.
Osteoporosis treatment drugs and targets.
| Type | Category | Drug | Target spot |
|---|---|---|---|
| Antiresorptive agent | Bisphosphonates | Alendronate Ibandranate Risedronate Zoledronate |
hydroxyapatite |
| RANKL inhibitor | Denosumab | RANKL | |
| Calcitonin | Calcitonin | OB | |
| Hormone | Estrogen | ER | |
| SERMs | Raloxifene | ER | |
| Tissue-specific estrogen complex | Bazedoxifene | ER | |
| Anabolic agent | Sclerostin inhibitor | Romosozumab-aqqg | Sclerostin |
| Parathyroid hormone analogs | Teriparatide | OC | |
| Parathyroid hormone-associated protein analogues | Abaloparatide | OC | |
| Potential drug | Active substance | Sirt3 inhibitor (70) | Sirt3 |
| Natural compound | Isosinensetin (71) | ROS | |
| Obacunone (44) | MIF | ||
| Active ingredients of traditional Chinese medicine | Boldine (72) | ATF pathway | |
| Icariside I (73) | OC, OB | ||
| Corylifol A (74) | ROS |